SAN FRANCISCO, Feb. 24, 2026 /PRNewswire/ — Docusign (Nasdaq: DOCU), the leader in AI-powered contract management, today announced that its Intelligent Agreement Management (IAM) platform is available as part of Anthropic’s Cowork. By connecting to Docusign in Cowork, businesses can securely create, review, send, and manage agreements from start to finish — all through natural language prompts in Cowork.

New Docusign Connector for Anthropic’s Claude, available in Cowork

This integration transforms how teams work with agreements, moving from passive summarization to active execution like drafting agreements, routing them for review, and triggering downstream actions across legal, sales, procurement, HR, and beyond.

“Docusign and Anthropic are raising the bar for agreement actions,” said Allan Thygesen, CEO of Docusign. “What Docusign brings to agentic experiences like Cowork is deep context across all business agreements — the intelligent workflows that know how to act on that context and the trust, security, and scale enterprises expect.”

“Cowork is designed to turn intent into action across complex, multi-step work,” said Matt Piccolella, Product Lead for Enterprise Apps at Anthropic. “Partnering with Docusign brings a leading system of record and execution for contracts into the Cowork experience, so people can confidently automate agreement workflows that matter most to their business.”

Here are just a few examples of what teams can accomplish:

• Use natural language to draft a contract from Docusign’s Master Service Agreement template, populate business details, and route it to Legal for review
• Instantly surface all customer contracts expiring in the next 90 days with a price increase clause, and take action directly from the results
• Review AI-suggested redlines on a service contract, align them to company policy, and trigger a vendor review workflow
• Request a summary report of all active contracts with a “data protection” clause and export it, formatted and ready to share
• Initiate a new customer onboarding workflow and get notified the moment identity verification is complete, without leaving Cowork

Empowering teams where they already work
Modern enterprises shouldn’t have to context-switch or choose between their preferred AI tools and their most critical agreement workflows. With Docusign natively integrated into Cowork, teams can execute sophisticated contract workflows without interrupting how and where they work.

Built on enterprise trust
The Docusign connector, built on the Model Context Protocol (MCP), brings enterprise-grade security to every agreement workflow in Cowork. Businesses must be authenticated by the platform, access is permission-based, and agreement data remains private and under the customer’s control.

The Docusign MCP connector is available today in beta globally, in English only, through Anthropic’s Connectors Directory for Docusign customers.

About Docusign
Docusign brings agreements to life. Nearly 1.8 million customers and more than a billion people in over 180 countries use Docusign solutions to accelerate the process of doing business and simplify people’s lives. With intelligent agreement management, Docusign unleashes business-critical data that is trapped inside of documents. Until now, these were disconnected from business systems of record, costing businesses time, money, and opportunity. Using Docusign’s IAM platform, companies can create, commit, and manage agreements with solutions created by the #1 company in e-signature and CLM. Learn more at www.docusign.com.

Media Contact:
Docusign Corporate Communications
media@docusign.com 

NYSE issues a pre-market daily advisory direct from the trading floor.

NEW YORK, Feb. 24, 2026 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

Ashley Mastronardi delivers the pre-market update on February 24th

• Equities are little changed this morning after President Trump’s 10% global levies officially went into effect early today.
• H&R Block CEO Curtis Campbell will join NYSE Live today to share why this tax season is particularly ‘complex.’
• Amer Sports says it delivered 27% revenue growth in 2025 during its Q4 earnings report. The firm’s executives join NYSE Live to break down the numbers.
• AI data intelligence platform DDN announces the appointment of Guido Torrini as Chief Financial Operating Officer. 

For market insights, IPO activity, and today’s opening bell, download the NYSE TV app at tv.nyse.com

Opening Bell
Lower East Side Partnership recognized for its continued dedication to keeping Lower Manhattan safe, including its ongoing snow preparedness and winter operations

Closing Bell
Covista (NYSE: CVSA) celebrates its Investor Day, name change, and trading under its new ticker

Click here to download the NYSE TV App

CONEXPO-CON/AGG leaders interviewed at NYSE.

Video – https://mma.prnasia.com/media2/2919196/NYSE_Market_Update_Feb_24.mp4

A strategic combination of the Florida SMA hub, Benco Dental’s network, SCHEU alliance, and FUGO’s multi-resin platform drives a global scale-up.

• Florida Production Hub: Establishing a domestic manufacturing base to provide localized, order-based SMA solutions for U.S. clinicians.
• Benco Dental Partnership: Unlocking a massive distribution network covering over 30,000 dental offices (23% of the U.S. market).
• Strategic Alliance with SCHEU Group: Partnering with Germany’s century-old industry leader to validate SMA technology and expand European market share.
  Introducing SMA mass production and ‘Simultaneous Multi-Resin Printing’ for monolithic full dentures via the FUGO centrifugal 3D printing platform.

NEW YORK and SEOUL, South Korea, Feb. 24, 2026 /PRNewswire/ — Specialized in 3D printing–based smart materials, Graphy Inc. (KOSDAQ: 318060, CEO Unseob Sim) designated 2026 as the company’s “Inaugural Year for U.S. Market Leadership” at LMT Lab Day 2026 and CDS 2026, held in Chicago from February 19 to 21. Building on a three-dimensional strategy that combines domestic production infrastructure, access to Tier-1 distribution networks, and proven technological reliability, Graphy is positioning itself as a definitive game-changer in the global clear aligner market.

Advancing into the U.S. Market: Delaware Subsidiary and Florida SMA Production Hub

The United States represents the world’s largest orthodontic market, with over six million new patients annually. Following the establishment of its Delaware subsidiary in September 2025, Graphy is now constructing an SMA-dedicated central lab and order-based production facility in Florida. This hub will provide an integrated “one-stop” service—from digital treatment planning to final appliance fabrication—within the U.S. By leveraging this domestic base, Graphy aims to secure more than 200 key clinic accounts in the second half of 2026, accelerating the localized adoption of SMA technology.

Benco Dental: Unlocking a Strategic Access to 23% of U.S. Dental Offices

A cornerstone of Graphy’s U.S. strategy is its new partnership with Benco Dental, the largest independent dental distributor in the United States. Benco serves over 30,000 clinics, representing approximately 23% of all U.S. dental offices. Through this alliance, Graphy’s shape-memory materials, comprehensive resin portfolio, and specialized equipment will gain immediate access to the mainstream market, utilizing Benco’s nationwide logistics network as a high-speed distribution “highway.”

Alliance with SCHEU Group: The Apex of Technical Credibility

Graphy also announced a landmark partnership with Germany’s SCHEU Group (SCHEU-DENTAL / Smile Dental), which celebrates its centennial in 2026. As a global benchmark for orthodontic technical standards, SCHEU Group’s adoption of Graphy’s SMA serves as a powerful validation of the material’s stability and precision. This agreement transcends a simple distribution deal; it represents formal recognition of Graphy’s innovation by one of Europe’s most trusted partners. Industry observers anticipate that combining SCHEU’s century-long brand equity with Graphy’s disruptive technology will drive a significant surge in European market share.

FUGO Platform: Revolutionary ‘Simultaneous Multi-Resin’ Printing

At the same event, Graphy showcased its collaboration with U.S.-based FUGO Precision 3D, demonstrating the superior performance of centrifugal 3D printing. The FUGO platform achieved ultra-precise control at the 10-micron level, producing “layer-less” surfaces with crystal-clear transparency that surpasses conventional 3D printing standards.

The highlight of the demonstration was the “Simultaneous Multi-Resin Printing” for monolithic full dentures. While traditional methods require separate printing and manual bonding of teeth and gingiva, Graphy’s material science combined with FUGO’s platform enables the fabrication of a single-piece denture in one print. This assembly-free process reduces labor requirements by over 80%, effectively delivering a manufacturing revolution for digital prosthetics.

A Graphy spokesperson commented, “The synergy between SCHEU’s 100-year legacy, Benco’s Tier-1 distribution power, and FUGO’s innovative production solutions will dramatically accelerate the clinical adoption of our SMA and digital prosthetic platforms. By delivering execution-driven results in the U.S. market, we will maximize shareholder value and solidify our momentum for global expansion.”

About Graphy Inc.

Graphy Inc. (KOSDAQ: 318060, CEO Unseob Sim), is a Seoul-based advanced materials company specializing in 3D-printed shape-memory photopolymer resins for orthodontics and digital dentistry.
As the pioneer of Shape Memory Aligners (SMA), Graphy enables body-temperature-activated orthodontic appliances that deliver consistent, biologically optimized forces.

By combining scientific rigor, proprietary materials, and strategic global partnerships, Graphy is building a scalable platform for next-generation digital dental manufacturing, serving clinicians, laboratories, and enterprise partners worldwide. 

– Media & Investor Relations

Graphy Inc.
Ace Gasan ForHu, 6F, 225 Gasan Digital 1-ro, Geumcheon-gu, Seoul
sales@itgraphy.com 
https://www.itgraphy.com 
https://www.graphysma.com/about 

– SNS

https://www.linkedin.com/company/itgraphy/

https://www.instagram.com/graphy_global/

https://www.facebook.com/graphyinc/

https://www.facebook.com/GraphyUnitedStates

https://www.youtube.com/@graphyinc

HAMILTON, ON, Feb. 24, 2026 /PRNewswire/ — AtomVie Global Radiopharma (AtomVie), a global leading radiopharmaceutical CDMO, announced that it has supplied the successful dosing of the first patient in Radiopharm Theranostics’ First-in-Human Phase 1/2a clinical study of 177Lu‑BetaBart (RV‑01) by providing GMP manufacturing and distribution services for the radiotherapeutic drug product, after successfully developing and qualifying the radiolabeling process and analytical methods using a phase-appropriate approach that expedited IND filing.

AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics’ Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01)

The Phase 1/2a clinical study is designed as a dose-escalation and expansion trial evaluating the safety, biodistribution, radiation dosimetry, and preliminary anti-tumor activity of 177Lu‑BetaBart, while also determining the recommended dose for future studies. 177Lu-BetaBart (RV‑01) is a 177Lutetium‑conjugated monoclonal antibody engineered to target the 4Ig isoform of B7‑H3, an immune checkpoint molecule overexpressed across multiple solid tumor types.

“Enabling the first patient dose of 177Lu-BetaBart reflects what matters most to us, ensuring that high‑quality radiopharmaceuticals are manufactured, released, and delivered on time so patients can access innovative therapies without delay,” said Bruno Paquin, Chief Executive Officer of AtomVie. “Our team is deeply focused on operational excellence and reliability, supporting our partners from early clinical development through global supply.”

“Dosing the first patient in the Phase 1/2a clinical study of 177Lu‑BetaBart represents an important milestone for Radiopharm Theranostics,” said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. “We appreciate AtomVie’s manufacturing expertise and commitment to quality as we advance BetaBart for patients with aggressive and difficult‑to‑treat solid tumors.”

About BetaBart (RV-01)

RV-01 is the first radiopharmaceutical therapeutic agent developed by Radiopharm Ventures, the Joint Venture formed between Radiopharm Theranostics and The University of Texas MD Anderson Cancer Center. 177Lu-BetaBart is a 177Lutetium-conjugated therapeutic that targets B7-H3, an immune checkpoint molecule that is overexpressed in several tumor types. Multiple preclinical studies with BetaBart have shown tumor shrinkage and prolonged survival in animals treated with the radiotherapeutic agent.

About the Phase 1/2a Clinical Trial

The FIH Phase 1/2a study (NCT07189871) is designed to establish the safety profile, biodistribution, pharmacokinetics, and radiation dosimetry of 177Lu-Betabart . The study aims to enroll 61 eligible participants who have a documented history of histopathologically confirmed castrate resistant prostate cancer, colorectal cancer, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell cancer, ovarian cancer, cervical cancer, endometrial cancer, triple negative breast cancer, or esophageal squamous cell carcinoma.

About Radiopharm Theranostics

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm Theranostics is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at radiopharmtheranostics.com.

For more information, please contact:
Riccardo Canevari, CEO & Managing Director
Phone number: +1 862 309 0293
e-mail id: rc@radiopharmtheranostics.com

About AtomVie(AtomVie)

AtomVie is a global leading CDMO for the GMP manufacturing and worldwide distribution of clinical and commercial radiopharmaceuticals. AtomVie offers the full range of scientific, technical, regulatory, quality and logistics services combined with a specialized infrastructure for the development of radiopharmaceuticals from clinical studies, phases I to III, to commercial markets. AtomVie currently serves international clients conducting clinical studies in over 28 countries worldwide. AtomVie is currently building and commissioning a new state-of-art, purpose-built 72,300 sq ft facility, set for operational readiness in H2 2026. For additional details visit our website https://www.atomvie.com/

For more information, please contact:
Tina Chainani, Business Development Manager
Phone number: +1 437 239 1288
e-mail id: tina.chainani@atomvie.com

TORONTO, Feb. 24, 2026 /PRNewswire/ — 3iQ Corp. (“3iQ”), a global pioneer in institutional digital asset investment solutions, is pleased to announce that the acquisition involving Coincheck Group N.V. (see press release from January 8, 2026 here) is now expected to close on or about February 28, 2026, notwithstanding the previously anticipated closing date of on or about April 1, 2026. 

Following 3iQ’s subsequent Notice to Unitholders issued on February 2, 2026 (the “Notice”), pursuant to the previously disclosed transaction (the “Proposed Transaction”), Coincheck Group N.V. (“the Purchaser”) will indirectly acquire all of the issued and outstanding Class A Common Shares and certain Class B Common Shares of 3iQ Digital Holdings Inc., 3iQ’s parent company (the “Parent”) from the Purchaser’s majority shareholder, Monex Group Inc., collectively representing approximately 96.77% of the issued and outstanding shares of the Parent and approximately 97.77% of the votes attaching to shares of the Parent, and may additionally directly acquire the remaining Class B Common Shares of the Parent, representing 3.23% of the issued and outstanding shares of the Parent and approximately 2.23% of the votes attaching to shares of the Parent from the remaining minority shareholders.

As previously communicated to unitholders of 3iQ in the Notice, following the completion of the Proposed Transaction, 3iQ will continue to be a wholly-owned subsidiary of the Parent, as the Parent controls the Purchaser. Consequently, the ultimate beneficial majority ownership of 3iQ is not changing, as Monex Group, Inc. owns more than 80% of the issued and outstanding shares of the Purchaser.  Additionally, the accelerated timing of the closing does not result in any immediate plans to change the investment objectives of 3iQ’s funds, increase the management fees or operating expenses paid by 3iQ’s funds, change service providers or change the role of 3iQ.

The accelerated closing does not require any action by the unitholders of 3iQ funds. 3iQ remains committed to maintaining continuity of operations and compliance with applicable securities laws.

About 3iQ Digital Asset Management

Founded in 2012, 3iQ is one of the world’s leading alternative digital asset managers, pioneering institutional-grade investments. 3iQ launched the world’s first Digital Assets Managed Account Platform (QMAP), a hedge fund investment solution, offering innovative risk-managed investment solutions to gain exposure to digital assets. 3iQ was also the first to launch a Bitcoin and Ethereum ETP listed on a major global stock exchange, integrate staking into its Ethereum and Solana ETPs boosting investor returns, and offering other regulated ETPs. In 2024, Monex Group, a leading Japanese financial group, took a majority stake in 3iQ. Since 2012, 3iQ has been at the forefront of innovation in digital asset investment management. To learn more about 3iQ, visit 3iq.io.

W: https://www.3iq.io/
L: https://www.linkedin.com/company/3iq-corp/
X: https://x.com/3iq_corp

Media Contacts for 3iQ

Europe
Angus Campbell
Nominis Advisory
angus@nominis.co

North America
Ryan Graham
JConnelly
+1 862-777-4274
rgraham@jconnelly.com

Julie Mercuro
JConnelly
+1 973-349-6471
jmercuro@jconnelly.com